Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18224261 | 1.00 | AKT1 (0.46) | AKT1ALDH1A1SMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL28385639 | 1.00 | AKT1 (0.46) | AKT1ALDH1A1SMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL28385636 | 1.00 | AKT1 (0.46) | AKT1ALDH1A1SMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL17003582 | 1.00 | AKT1 (0.46) | AKT1ALDH1A1SMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL26502773 | 0.96 | AKT1 (0.48) | AKT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL38658781 | 0.94 | AKT1 (0.46) | AKT1 | |
| SCHEMBL38658475 | 0.94 | AKT1 (0.46) | AKT1 | |
| SCHEMBL22452943 | 0.93 | AKT1 (0.47) | AKT1ALDH1A1SMN1; SMN2OPRD1OPRM1 | |
| SCHEMBL22452940 | 0.93 | AKT1 (0.47) | AKT1ALDH1A1SMN1; SMN2OPRD1OPRM1 | |
| SCHEMBL20345224 | 0.93 | AKT1 (0.45) | AKT1ALDH1A1SMN1; SMN2OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113929738-A | Antibody-drug conjugates | 第一三共株式会社 | 2022-01-14 | — | — | CN | claimed |
| CN-113527418-B | Preparation method of ADC linker | 成都普康唯新生物科技有限公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-113527418-A | Preparation method of ADC linker | 成都普赛唯新生物科技有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20200385422-A1 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-12-10 | — | — | US | disclosed |
| CN-111051330-A | Improved preparation method of antibody-drug conjugate | 第一三共株式会社 | 2020-04-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385422-A1 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | UGT1A9, ALB, MRPL21 | AKT1 4696/4885ALDH1A1 257/4885SMN1; SMN2 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.